



# Carnitine/Acylcarnitine Standards and Mixtures

## For Identification and Quantification



Carnitines and acylcarnitines play an essential role in fatty acid metabolism. Metabolic disorders of fatty acid oxidation and various organic acidurias arising from carnitine/acylcarnitine accumulation impose major clinical manifestations (e.g., hypoketotic hypoglycemia, skeletal myopathy, liver disease). These are largely attributed to enzymatic deficiencies and can be monitored through carnitine/acylcarnitine measurement.

**To aid MS/MS screening developments and applications, Cambridge Isotope Laboratories, Inc. (CIL) is pleased to offer a variety of well characterized, stable isotope-labeled (and unlabeled) carnitine/acylcarnitine standards and mixes.** These are available in different labeling patterns in their neat form. For a complete listing, visit [isotope.com](http://isotope.com).

### Individual Standards

| Catalog No.            | Description  | Abbreviation |
|------------------------|--|--------------|
| DLM-1871               | L-Carnitine-HCl (methyl-D <sub>3</sub> , 98%)  | C0           |
| DLM-3820               | L-Carnitine-HCl (dimethyl-D <sub>6</sub> , 98%)  | C0           |
| DLM-10962              | L-Carnitine-HCl (trimethyl-D <sub>9</sub> , 98%)   | C0           |
| DLM-3555               | L-Carnitine (trimethyl-D <sub>9</sub> , 98%)   | C0           |
| DLM-754                | L-Carnitine-HCl, O-acetyl (N-methyl-D <sub>3</sub> , 98%)  | C2           |
| DLM-3821               | L-Carnitine-HCl, O-acetyl (N,N-dimethyl-D <sub>6</sub> , 98%) CP 97%   | C2           |
| DLM-3973               | L-Carnitine-HCl, O-propionyl (N-methyl-D <sub>3</sub> , 98%)   | C3           |
| DLM-11049              | L-Carnitine-CIO <sub>4</sub> , O-malonyl (N-methyl-D <sub>3</sub> , 98%)                                     | C3-DC        |
| DLM-3861               | L-Carnitine-HCl, O-butyryl (N-methyl-D <sub>3</sub> , 98%)   | C4           |
| DLM-11713              | L-Carnitine, O-3-hydroxybutyryl (N-methyl-D <sub>3</sub> , 98%) CP 95%                                       | C4-OH        |
| DLM-3974               | L-Carnitine-HCl, O-isovaleryl (N,N,N-trimethyl-D <sub>9</sub> , 98%)   | C5           |
| DLM-12325              | L-Carnitine-CIO <sub>4</sub> , tiglyl (N,N,N-trimethyl-D <sub>9</sub> , 98%) CP 90%                          | C5:1         |
| DLM-3975               | L-Carnitine (mono-CIO <sub>4</sub> ), O-glutaryl (N-methyl-D <sub>3</sub> , 98%) CP 97%                      | C5-DC        |
| DLM-8272               | L-Carnitine-CIO <sub>4</sub> , 3-hydroxyisovaleryl (N-methyl-D <sub>3</sub> , 98%)                           | C5-OH        |
| DLM-9276               | L-Carnitine-HCl, O-hexanoyl (N-methyl-D <sub>3</sub> , 98%)  | C6           |
| DLM-755                | L-Carnitine-HCl, O-octanoyl (N-methyl-D <sub>3</sub> , 98%)  | C8           |
| DLM-9067               | L-Carnitine-HCl, O-decanoyl (N-methyl-D <sub>3</sub> , 98%)  | C10          |
| <b>NEW!</b> CNLM-11665 | L-Carnitine-HCl, O-decanoyl (trimethyl- <sup>13</sup> C <sub>3</sub> , 98%; <sup>15</sup> N, 98%) CP 95%     | C10          |
| DLM-8746               | L-Carnitine-HCl, O-dec-2-enoyl (N,N,N-trimethyl-D <sub>9</sub> , 98%) 95% E                                  | C10:1        |
| DLM-8162               | L-Carnitine-HCl, O-dodecanoyl (N-methyl-D <sub>3</sub> , 98%)  | C12          |
| DLM-8215               | L-Carnitine-HCl, O-dodecanoyl (N,N,N-trimethyl-D <sub>9</sub> , 98%)   | C12          |
| DLM-4425               | L-Carnitine-HCl, O-myristoyl (N,N,N-trimethyl-D <sub>9</sub> , 98%)  | C14          |
| DLM-12326              | L-Carnitine-CIO <sub>4</sub> , tetradec-5-cis-enoyl (N,N,N-trimethyl-D <sub>9</sub> , 98%) CP 90%            | C14:1        |
| DLM-1263               | L-Carnitine-HCl, O-palmitoyl (N-methyl-D <sub>3</sub> , 98%)   | C16          |
| DLM-9189               | L-Carnitine (mono-CIO <sub>4</sub> ), O-3-DL-hydroxypalmitoyl (N-methyl-D <sub>3</sub> , 98%)                | C16-OH       |
| DLM-8271               | L-Carnitine-HCl, O-octadecanoyl (N-methyl-D <sub>3</sub> , 98%)  | C18          |
| <b>NEW!</b> CNLM-11666 | L-Carnitine-HCl, O-octadecanoyl (trimethyl- <sup>13</sup> C <sub>3</sub> , 98%; <sup>15</sup> N, 98%) CP 95% | C18          |
| <b>NEW!</b> DLM-11594  | L-Carnitine, O-hexacosanoyl (N-methyl-D <sub>3</sub> , 98%) CP 95%   | C26          |
| <b>NEW!</b> DLM-11741  | L-Carnitine-CIO <sub>4</sub> , O-hexacosanoyl (N-methyl-D <sub>3</sub> , 98%) CP 95%                         | C26          |
| DLM-11174              | L-Carnitine-HCl, O-hexacosanoyl (N,N,N-trimethyl-D <sub>9</sub> , 98%) CP 95%                                | C26          |

Continued >

## Mixtures

| Catalog No. | Description                                 | No. of Metabolites | Unit Size        |
|-------------|---|--------------------|------------------|
| NSK-B       | Carnitine/Acylcarnitine Standards Mix Set B | 8                  | 1 vial, 10 vials |

| Standard  | Abbreviation | Conc. (µM) |
|---|--------------|------------|
| L-Carnitine (trimethyl-D <sub>3</sub> , 98%)                        | C0           | 152        |
| O-Acetyl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)            | C2           | 38         |
| O-Propionyl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)         | C3           | 7.6        |
| O-Butyryl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)           | C4           | 7.6        |
| O-Isovaleryl-L-carnitine·HCl (N,N,N-trimethyl-D <sub>3</sub> , 98%) | C5           | 7.6        |
| O-Octanoyl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)          | C8           | 7.6        |
| O-Myristoyl-L-carnitine·HCl (N,N,N-trimethyl-D <sub>3</sub> , 98%)  | C14          | 7.6        |
| O-Palmitoyl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)         | C16          | 15.2       |

|          |   |   |                  |
|----------|---|---|------------------|
| NSK-B-G1 | Carnitine/Acylcarnitine Standards Mix Supplement to NSK-B | 5 | 1 vial, 10 vials |
|----------|---|---|------------------|

| Standard   | Abbreviation | Conc. (µM) |
|--|--------------|------------|
| O-Glutaryl-L-carnitine·ClO <sub>4</sub> (N-methyl-D <sub>3</sub> , 98%) CP 97%       | C5-DC        | 15.2       |
| 3-Hydroxyisovaleryl-L-carnitine·ClO <sub>4</sub> (N-methyl-D <sub>3</sub> , 98%)     | C5-OH        | 7.6        |
| O-Dodecanoyl-L-carnitine·HCl (N,N,N-trimethyl-D <sub>3</sub> , 98%)                  | C12          | 7.6        |
| O-3-DL-Hydroxypalmitoyl-L-carnitine·ClO <sub>4</sub> (N-methyl-D <sub>3</sub> , 98%) | C16-OH       | 15.2       |
| O-Octadecanoyl-L-carnitine·HCl (N-methyl-D <sub>3</sub> , 98%)                       | C18          | 15.2       |

**Note:** Companion unlabeled mixes and sets are also available; please inquire.

## Individual Standards

### Example References

He, W.; Berthiaume, J.M.; Previs, S.; et al. **2023**. Ischemia promotes acyl-CoAs dephosphorylation and propionyl-CoA accumulation. *Metabolomics*, 19(2), 12-26.

Mak, J.; Peng, G.; Le, A.; et al. **2023**. Validation of a targeted metabolomics panel for improved second-tier newborn screening. *J Inherit Metab Dis*, 46(2), 194-205.

Al-Riyami, S.; Al-Manei, M.; Al-Fahdi, A.; et al. **2022**. Establishment and validation of reference values for amino acids and acylcarnitines in dried blood spots for Omani newborns using tandem mass spectrometry. *Oman Med J*, 37(5), e426-e432.

Wang, W.Y.; Liu, X.; Gao, X-Q.; et al. **2022**. Relationship between acylcarnitine and the risk of retinopathy in type 2 diabetes mellitus. *Front Endocrinol*, 13, 834205-834213.

## Mixtures

### Example References

Tan, H.C.; Hsu, J.W.; Tai, E.S.; et al. **2024**. The impact of obesity-associated glycine deficiency on the elimination of endogenous and exogenous metabolites via the glycine conjugation pathway. *Front Endocrinol*, 15, 1343738-1343749.

Zong, G.-W.; Wang, W.-Y.; Zheng, J.; et al. **2023**. A metabolism-based interpretable machine learning prediction model for diabetic retinopathy risk: a cross-sectional study in Chinese patients with type 2 diabetes. *J Diabetes Res*, 2023, 3990035-3990046.

Pruss, K.M.; Chen, H.; Liu, Y.; et al. **2023**. Host-microbe co-metabolism via MCAD generates circulating metabolites including hippuric acid. *Nat Commun*, 14(1), 512-523.

Mak, J.; Peng, G.; Le, A.; et al. **2023**. Validation of a targeted metabolomics panel for improved second-tier newborn screening. *J Inherit Metab Dis*, 46(2), 194-205.

Huguenard, C.J.C.; Cseresznye, A.; Darcey, T.; et al. **2023**. Age and APOE affect L-carnitine system metabolites in the brain in the APOE-TR model. *Front Aging Neurosci*, 14, 1059017-1059035.

### Technical Note

Xie, X.; Kozak, M. **2020**. Simultaneous analysis of amino acids, acylcarnitines, and succinylacetone in dried blood spots for research using nonderivatized and derivatized methods. (Thermo Scientific technical note #73398).

Chemical purity (CP) is 98% or greater, unless otherwise specified.

For research use only. Not for use in diagnostic procedures.



Cambridge Isotope Laboratories, Inc. 3 Highwood Drive, Tewksbury, MA 01876 USA

North America: 1.800.322.1174 | International: +1.978.749.8000 | fax: +1.978.749.2768 | isotope.com

MSMS\_CARNITINE\_ACYLCARNITINE (10/22/24)  
Supersedes all previously published literature